BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72 Suppl 1:2-15. [PMID: 18087177 DOI: 10.1159/000111702] [Cited by in Crossref: 136] [Cited by in F6Publishing: 122] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Choi J, Kim PN, Jeong WK, Kim HC, Yang DM, Cha SH, Chung J. Establishing Cutoff Values for a Quality Assurance Test Using an Ultrasound Phantom in Screening Ultrasound Examinations for Hepatocellular Carcinoma: An Initial Report of a Nationwide Survey in Korea. Journal of Ultrasound in Medicine 2011;30:1221-9. [DOI: 10.7863/jum.2011.30.9.1221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Rhim H, Lim HK. Radiofrequency ablation of hepatocellular carcinoma: pros and cons. Gut Liver 2010;4 Suppl 1:S113-8. [PMID: 21103289 DOI: 10.5009/gnl.2010.4.S1.S113] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
3 Tanimoto A, Min Lee J, Murakami T, Huppertz A, Kudo M, Grazioli L. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 2009;19:975-89. [DOI: 10.1007/s00330-009-1624-y] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 6.5] [Reference Citation Analysis]
4 Vullierme MP, Paradis V, Chirica M, Castaing D, Belghiti J, Soubrane O, Barbare JC, Farges O. Hepatocellular carcinoma--what's new? J Visc Surg. 2010;147:e1-e12. [PMID: 20595072 DOI: 10.1016/j.jviscsurg.2010.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
5 Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1779-1786. [PMID: 21875430 DOI: 10.1111/j.1440-1746.2011.06891.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
6 Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R, Chen Y, Gao X, Zhu Q, Yue X, Pan Q, Xu S, Li J, Huang M, Daugherty-Holtrop J, He Y, Xu HE, Fan J, Ding J, Geng M. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst 2011;103:1696-712. [PMID: 22025622 DOI: 10.1093/jnci/djr360] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
7 Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, Shiraha H, Kuwaki K, Hagihara H, Ikeda F. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2012;47:421-426. [PMID: 22048256 DOI: 10.1007/s00535-011-0492-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
8 Minami Y, Kudo M. Radiofrequency ablation of liver metastases from colorectal cancer: a literature review. Gut Liver 2013;7:1-6. [PMID: 23422905 DOI: 10.5009/gnl.2013.7.1.1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
9 Inoue T, Kudo M, Maenishi O, Komuta M, Nakashima O, Kojiro M, Maekawa K. Value of liver parenchymal phase contrast-enhanced sonography to diagnose premalignant and borderline lesions and overt hepatocellular carcinoma. AJR Am J Roentgenol 2009;192:698-705. [PMID: 19234266 DOI: 10.2214/AJR.07.3282] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
10 Chai B, Wang W, Wang F, Zhou G, Zheng C. Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma. Int J Hyperthermia 2021;38:1685-94. [PMID: 34843653 DOI: 10.1080/02656736.2021.1970825] [Reference Citation Analysis]
11 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
12 Kim KA, Kim MJ, Choi JY, Chung YE. Development of hepatocellular carcinomas in patients with absence of tumors on a prior ultrasound examination. Eur J Radiol. 2012;81:1450-1454. [PMID: 21514759 DOI: 10.1016/j.ejrad.2011.03.053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
13 Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Henmi S, Sakamoto A, Ishikawa T, Saito S, Kita R, Kimura T. Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2012; 18(12): 1379-1384 [PMID: 22493552 DOI: 10.3748/wjg.v18.i12.1379] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
14 Lee MW, Kim YJ, Park HS, Yu NC, Jung SI, Ko SY, Jeon HJ. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol. 2010;194:W396-W400. [PMID: 20410384 DOI: 10.2214/ajr.09.3171] [Cited by in Crossref: 66] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
15 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Saito M, Seo Y, Yano Y, Momose K, Hirano H, Yoshida M, Azuma T. Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment. PLoS One 2013;8:e55441. [PMID: 23520445 DOI: 10.1371/journal.pone.0055441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Hsieh CB, Chen TW, Chu CM, Chu HC, Yu CP, Chung KP. Is inconsistency of α-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence? World J Gastroenterol 2010; 16(24): 3049-3055 [PMID: 20572309 DOI: 10.3748/wjg.v16.i24.3049] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98:1210-1224. [PMID: 21766289 DOI: 10.1002/bjs.7669] [Cited by in Crossref: 170] [Cited by in F6Publishing: 165] [Article Influence: 15.5] [Reference Citation Analysis]
19 Nagano H, Kobayashi S, Marubashi S, Wada H, Eguchi H, Tanemura M, Tomimaru Y, Umeshita K, Doki Y, Mori M. Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus. Exp Ther Med 2013;5:3-10. [PMID: 23251233 DOI: 10.3892/etm.2012.736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
20 Inoue T, Kudo M, Komuta M, Hayaishi S, Ueda T, Takita M, Kitai S, Hatanaka K, Yada N, Hagiwara S, Chung H, Sakurai T, Ueshima K, Sakamoto M, Maenishi O, Hyodo T, Okada M, Kumano S, Murakami T. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012;47:1036-47. [DOI: 10.1007/s00535-012-0571-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
21 Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T, Itakura J, Nakanishi H, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, Sakamoto M, Izumi N. Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. Oncology 2011;80:278-88. [DOI: 10.1159/000328448] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
22 Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, Shibata H, Shimoe T, Matsuda T, Toshikuni N, Fujioka S, Ohmoto K, Nakamura S, Kariyama K, Aikata H, Kobayashi Y, Tsutsui A. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients: Complications of RFA for HCC. Hepatology Research 2012;42:1058-64. [DOI: 10.1111/j.1872-034x.2012.01025.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
23 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
25 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
26 de Baere T, Deschamps F. Arterial therapies of colorectal cancer metastases to the liver. Abdom Imaging 2011;36:661-70. [PMID: 21681492 DOI: 10.1007/s00261-011-9768-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
27 Takayasu K. Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. Oncology 2011;81 Suppl 1:105-10. [PMID: 22212943 DOI: 10.1159/000333269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
28 Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX; World Federation for Ultrasound in Medicine., European Federation of Societies for Ultrasound. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013;39:187-210. [PMID: 23137926 DOI: 10.1016/j.ultrasmedbio.2012.09.002] [Cited by in Crossref: 416] [Cited by in F6Publishing: 382] [Article Influence: 41.6] [Reference Citation Analysis]
29 Rempp H, Boss A, Helmberger T, Pereira P. The current role of minimally invasive therapies in the management of liver tumors. Abdom Imaging. 2011;36:635-647. [PMID: 21562884 DOI: 10.1007/s00261-011-9749-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
30 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35 Suppl 1:129-138. [PMID: 25529098 DOI: 10.1111/liv.12713] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
31 Nanashima A, Tobinaga S, Masuda J, Miyaaki H, Taura N, Takeshita H, Hidaka S, Sawai T, Nakao K, Nagayasu T. Selecting treatment for hepatocellular carcinoma based on the results of hepatic resection and local ablation therapy. J Surg Oncol 2010;101:481-5. [PMID: 20191611 DOI: 10.1002/jso.21523] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
32 Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744-751. [PMID: 20060710 DOI: 10.1016/j.ejca.2009.12.018] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
33 Yamaguchi S, Tsutsui K, Satake K, Morikawa S, Shirai Y, Tanaka HT. Dynamic analysis of a needle insertion for soft materials: Arbitrary Lagrangian–Eulerian-based three-dimensional finite element analysis. Computers in Biology and Medicine 2014;53:42-7. [DOI: 10.1016/j.compbiomed.2014.07.012] [Cited by in Crossref: 18] [Article Influence: 2.3] [Reference Citation Analysis]
34 Kudo M. Diagnostic imaging of hepatocellular carcinoma: Recent progress. Oncology. 2011;81 Suppl 1:73-85. [PMID: 22212940 DOI: 10.1159/000333265] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
35 Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, Wu CC, Wu CH, Ho YS, Yang YY, Chang YJ. Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression. Ann Surg Oncol 2010;17:3379-85. [PMID: 20625840 DOI: 10.1245/s10434-010-1163-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
36 Morota K, Komori M, Fujinami R, Yamada K, Kuribayashi K, Watanabe N, Sokoll LJ, Elliott D, Chan DW, Martens F, Heijboer AC, Blankenstein MA, Hershberger SJ, Pfeiffer ZA, Vaidya SV, Dowell BL. Improvement and multicenter evaluation of the analytical performance of an automated chemiluminescent immunoassay for alpha fetoprotein. Int J Biol Markers 2012;27:39-46. [PMID: 22020369 DOI: 10.5301/JBM.2011.8738] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Takeuchi Y, Ikeda F, Moritou Y, Hagihara H, Yasunaka T, Kuwaki K, Miyake Y, Ohnishi H, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Nouso K, Yamamoto K. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol 2013;48:405-12. [PMID: 22869157 DOI: 10.1007/s00535-012-0647-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
38 Pugacheva O, Matsui O, Kozaka K, Minami T, Ryu Y, Koda W, Kobayashi S, Gabata T. Detection of small hypervascular hepatocellular carcinomas by EASL criteria: Comparison with double-phase CT during hepatic arteriography. European Journal of Radiology 2011;80:e201-6. [DOI: 10.1016/j.ejrad.2010.08.036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
39 Inoue T, Kudo M, Hatanaka K, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T. Usefulness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: comparison with dynamic CT. Oncology. 2013;84 Suppl 1:51-57. [PMID: 23428859 DOI: 10.1159/000345890] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
40 Kawamura R, Seki T, Umehara H, Ikeda K, Inokuchi R, Asayama T, Yamaguchi T, Takahashi Y, Sakao M, Lencioni R. Combined treatment of large hepatocellular carcinoma with transcatheter arterial chemoembolization and percutaneous ethanol injection with a multipronged needle: experimental and clinical investigation. Cardiovasc Intervent Radiol. 2012;35:325-333. [PMID: 21607824 DOI: 10.1007/s00270-011-0184-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
41 Hino-Arinaga T, Ide T, Kuromatsu R, Miyajima I, Ogata K, Kuwahara R, Hisamochi A, Torimura T, Sata M; Autoimmune Hepatitis Study Group. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1. J Gastroenterol. 2012;47:569-576. [PMID: 22187167 DOI: 10.1007/s00535-011-0519-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
42 Huo TI, Huang YH, Hsia CY, Su CW, Lin HC, Hsu CY, Lee PC, Lui WY, Loong CC, Chiang JH, Chiou YY, Lee SD. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection? Liver Int 2009;29:767-73. [PMID: 19018974 DOI: 10.1111/j.1478-3231.2008.01908.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
43 Kudo M. Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology. 2011;81 Suppl 1:1-10. [PMID: 22212929 DOI: 10.1159/000333252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
44 Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K. Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. World J Gastroenterol 2012; 18(12): 1385-1390 [PMID: 22493553 DOI: 10.3748/wjg.v18.i12.1385] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
45 Lee CR, Lim JH, Kim SH, Ahn SH, Park YN, Choi GH, Choi JS, Kim KS. A comparative analysis of hepatocellular carcinoma after hepatic resection in young versus elderly patients. J Gastrointest Surg. 2012;16:1736-1743. [PMID: 22810298 DOI: 10.1007/s11605-012-1966-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
46 Ozenne V, Bouattour M, Goutté N, Vullierme MP, Ripault MP, Castelnau C, Valla DC, Degos F, Farges O. Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis. 2011;43:1001-1005. [PMID: 21798829 DOI: 10.1016/j.dld.2011.06.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
47 Kawaguchi T, Kakuma T, Yatsuhashi H, Watanabe H, Saitsu H, Nakao K, Taketomi A, Ohta S, Tabaru A, Takenaka K, Mizuta T, Nagata K, Komorizono Y, Fukuizumi K, Seike M, Matsumoto S, Maeshiro T, Tsubouchi H, Muro T, Inoue O, Akahoshi M, Sata M. Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma: Data mining of non-HBV/non-HCV-related HCC. Hepatology Research 2011;41:564-71. [DOI: 10.1111/j.1872-034x.2011.00799.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Vogl TJ, Naguib NN, Nour-eldin NA, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications. European Journal of Radiology 2009;72:505-16. [DOI: 10.1016/j.ejrad.2008.08.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 6.5] [Reference Citation Analysis]
49 Kuo YH, Lu SN, Hung CH, Kee KM, Chen CH, Hu TH, Lee CM, Changchien CS, Wang JH. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatol Int 2010;4:700-6. [PMID: 21286340 DOI: 10.1007/s12072-010-9223-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
50 Park YN, Kim MJ. Hepatocarcinogenesis: imaging-pathologic correlation. Abdom Imaging. 2011;36:232-243. [PMID: 21267560 DOI: 10.1007/s00261-011-9688-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
51 Kim HY, Park J. Molecularly Targeted Therapies for Hepatocellular Carcinoma: Sorafenib as a Stepping Stone. Dig Dis 2011;29:303-9. [DOI: 10.1159/000327563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
52 Kato K, Abe H, Ika M, Yonezawa T, Sato Y, Hanawa N, Shimizu S, Endo S, Matsuo R, Tsubota A. C-Arm Cone Beam Computed Tomography Guidance for Radiofrequency Ablation in Hepatocellular Carcinoma. Oncology. 2017;92:142-152. [PMID: 28052301 DOI: 10.1159/000453665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
53 Kudo M. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol. 2010;25:439-452. [PMID: 20370723 DOI: 10.1111/j.1440-1746.2009.06207.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
54 Yao N, Yao D, Wang L, Dong Z, Wu W, Qiu L, Yan X, Yu D, Chen J, Sai W. Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression. Tumour Biol. 2012;33:1767-1776. [PMID: 22684773 DOI: 10.1007/s13277-012-0436-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
55 Qin Y, Xu S, Pan D, Ye G, Wu C, Wang S, Wang C, Jiang J, Fu J. Silencing of WWP2 inhibits adhesion, invasion, and migration in liver cancer cells. Tumor Biol 2016;37:6787-99. [DOI: 10.1007/s13277-015-4547-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, Takemura S, Tabata Y, Murata K. Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rabbits. Eur J Radiol 2009;72:534-40. [PMID: 18778907 DOI: 10.1016/j.ejrad.2008.07.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
57 Kemeny N, Kurilova I, Li J, Camacho JC, Sofocleous CT. Liver-Directed and Systemic Therapies for Colorectal Cancer Liver Metastases. Cardiovasc Intervent Radiol 2019;42:1240-54. [DOI: 10.1007/s00270-019-02284-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. Journal of Gastroenterology and Hepatology 2010;25:657-63. [DOI: 10.1111/j.1440-1746.2009.06167.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 7.6] [Reference Citation Analysis]
59 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012;4:381-6. [PMID: 23181103 DOI: 10.3892/etm.2012.611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
60 Saito M, Seo Y, Yano Y, Miki A, Yoshida M, Azuma T. Short-term reductions in non-protein respiratory quotient and prealbumin can be associated with the long-term deterioration of liver function after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol 2012;47:704-14. [DOI: 10.1007/s00535-012-0535-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
61 Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K. Surgical treatment of extrahepatic recurrence of hepatocellular carcinoma. Langenbecks Arch Surg. 2014;399:1057-1064. [PMID: 25030500 DOI: 10.1007/s00423-014-1230-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
62 Goel M, Gaikwad V, Dharia T, Kulkarni S, Shetty N, Shrikhande SV. Preresection transarterial chemoembolization for hepatocellular carcinoma: an experience with 23 patients. Indian J Gastroenterol 2014;33:432-9. [PMID: 25037076 DOI: 10.1007/s12664-014-0490-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
63 Sangro B, D'avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2011;12:1057-73. [DOI: 10.1517/14656566.2011.545346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
64 Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2008;2:779-88. [PMID: 19707458 DOI: 10.2147/btt.s3410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 0.3] [Reference Citation Analysis]
65 Shen Y, Hsu C, Cheng A. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807. [DOI: 10.1007/s00535-010-0270-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
66 Abe H, Aida Y, Seki N, Sugita T, Tomita Y, Nagano T, Itagaki M, Sutoh S, Nagatsuma K, Itoh K, Matsuura T, Aizawa Y. Aldehyde dehydrogenase 2 polymorphism for development to hepatocellular carcinoma in East Asian alcoholic liver cirrhosis. J Gastroenterol Hepatol 2015;30:1376-83. [PMID: 25778454 DOI: 10.1111/jgh.12948] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
67 Matsuo N, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 2009;9:240. [PMID: 19615090 DOI: 10.1186/1471-2407-9-240] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 6.5] [Reference Citation Analysis]
68 Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2010;30:166-174. [PMID: 19912531 DOI: 10.1111/j.1478-3231.2009.02166.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
69 Marrero JA, Feng Z. Alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2010;138:400-1. [PMID: 19932214 DOI: 10.1053/j.gastro.2009.08.076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
70 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
71 Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109-1113. [PMID: 31336394 DOI: 10.1111/hepr.13411] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 37.0] [Reference Citation Analysis]
72 Yoo HJ, Lee JM, Lee JY, Kim SH, Kim SJ, Han JK, Choi BI. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver. Invest Radiol. 2009;44:800-807. [PMID: 19838119 DOI: 10.1097/rli.0b013e3181bc271d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
73 Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, Kudo M. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011;84 Suppl 1:43-49. [PMID: 22156485 DOI: 10.1159/000333212] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
74 Yeow GPV, Yeow DGE, Sankaran P, Maiyauen T, Sharif MS. Hemorrhagic extrahepatic recurrence of hepatocellular carcinoma: A case report. Ann Hepatobiliary Pancreat Surg 2019;23:77-9. [PMID: 30863813 DOI: 10.14701/ahbps.2019.23.1.77] [Reference Citation Analysis]
75 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Limaiem F, Bouhamed M, Sahraoui G, Mzabi S. Hepatocellular carcinoma: a clinicopathological study of 64 cases. Pan Afr Med J 2017;27:41. [PMID: 28761617 DOI: 10.11604/pamj.2017.27.41.9584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Wong GLH, Xu HX, Xie XY. Detection Of Focal Liver Lesions In Cirrhotic Liver Using Contrast-Enhanced Ultrasound. World J Radiol 2009; 1(1): 25-36 [PMID: 21160718 DOI: 10.4329/wjr.v1.i1.25] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
78 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 685] [Article Influence: 57.0] [Reference Citation Analysis]
79 Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. Oncology. 2013;84 Suppl 1:28-33. [PMID: 23428855 DOI: 10.1159/000345886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
80 Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25:1426-1434. [PMID: 20659234 DOI: 10.1111/j.1440-1746.2010.06285.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
81 Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063. [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
82 Yoon SH, Lee JM, So YH, Hong SH, Kim SJ, Han JK, Choi BI. Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol. 2009;193:W482-W489. [PMID: 19933622 DOI: 10.2214/ajr.08.1818] [Cited by in Crossref: 85] [Cited by in F6Publishing: 36] [Article Influence: 7.1] [Reference Citation Analysis]
83 Kitai S, Kudo M, Minami Y, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Takahashi S, Asakuma Y. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology. 2008;51 Suppl 1:86-94. [PMID: 18544953 DOI: 10.1159/000122599] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
84 Jin YJ, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY, Ahn SI, Shin WY, Cho SG, Jeon YS. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg. 2014;18:555-561. [PMID: 24420729 DOI: 10.1007/s11605-013-2440-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
85 Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31-39. [PMID: 24159594 DOI: 10.1159/000346220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
86 Takeshita S, Ichikawa T, Nakao K, Miyaaki H, Shibata H, Matsuzaki T, Muraoka T, Honda T, Otani M, Akiyama M, Miuma S, Ozawa E, Fujimito M, Eguchi K. A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. Nutr Res. 2009;29:89-93. [PMID: 19285598 DOI: 10.1016/j.nutres.2008.12.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
87 Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166. [PMID: 25752327 DOI: 10.1111/liv.12818] [Cited by in Crossref: 369] [Cited by in F6Publishing: 383] [Article Influence: 52.7] [Reference Citation Analysis]
88 Shi Y, Sun X, He X. Overexpression of Aristaless-Like Homeobox-4 Inhibits Proliferation, Invasion, and EMT in Hepatocellular Carcinoma Cells. Oncol Res 2017;25:11-8. [PMID: 28081728 DOI: 10.3727/096504016X14685034103833] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
89 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
90 Shiozawa K, Watanabe M, Takayama R, Takahashi M, Wakui N, Iida K, Sumino Y. Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. J Clin Ultrasound 2010;38:182-9. [PMID: 20232404 DOI: 10.1002/jcu.20685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
91 Wang Y, Luo Q, Li Y, Wang H, Deng S, Wei S, Li X. Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer. PLoS One. 2014;9:e103939. [PMID: 25105961 DOI: 10.1371/journal.pone.0103939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
92 Tomiyama Y, Yoshioka N, Yanai Y, Kawase T, Nishina S, Hara Y, Yoshida K, Korenaga K, Korenaga M, Hino K. Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma. Hepat Med 2011;3:45-52. [PMID: 24367220 DOI: 10.2147/HMER.S19695] [Reference Citation Analysis]
93 Maiwald B, Lobsien D, Kahn T, Stumpp P. Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma? PLoS One. 2014;9:e111935. [PMID: 25375778 DOI: 10.1371/journal.pone.0111935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
94 Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016;36 Suppl 1:124-129. [PMID: 26725909 DOI: 10.1111/liv.13028] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
95 Bashir MR, Huang R, Mayes N, Marin D, Berg CL, Nelson RC, Jaffe TA. Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications: LI-RADS vs. OPTN Categorization. J Magn Reson Imaging 2015;42:305-14. [DOI: 10.1002/jmri.24793] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
96 Kim YS, Lim HK, Rhim H, Lee MW. Ablation of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014;28:897-908. [PMID: 25260316 DOI: 10.1016/j.bpg.2014.08.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
97 Noda T, Eguchi H, Iwagami Y, Yamada D, Asaoka T, Gotoh K, Kawamoto K, Kobayashi S, Hashimoto Y, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Minimally invasive liver resection for hepatocellular carcinoma of patients with liver damage B: A propensity score-based analysis. Hepatol Res 2018;48:539-48. [PMID: 29316082 DOI: 10.1111/hepr.13057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
98 Enomoto S, Tamai H, Shingaki N, Mori Y, Moribata K, Shiraki T, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis. Hepatol Int 2011;5:730-7. [PMID: 21484138 DOI: 10.1007/s12072-010-9245-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
99 Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88:530-549. [PMID: 23921081 DOI: 10.1016/j.critrevonc.2013.07.003] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
100 Kudo M, Chung H. Single HCC between 2 and 5 cm: the grey zone: hepatologist’s perspective. J Hepatobiliary Pancreat Sci. 2010;17:434-437. [PMID: 19902137 DOI: 10.1007/s00534-009-0242-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
101 Kudo M. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Dig Dis. 2011;29:273-277. [PMID: 21829017 DOI: 10.1159/000327558] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
102 Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N, Mizushima T, Higashi T, Tanimoto M. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. Oncology 2011;81:39-44. [PMID: 21912196 DOI: 10.1159/000331411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
103 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 47] [Article Influence: 11.7] [Reference Citation Analysis]
104 Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 2011;81 Suppl 1:134-40. [PMID: 22212947 DOI: 10.1159/000333276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
105 Kim MJ. Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma. Gut Liver 2011;5:15-21. [PMID: 21461067 DOI: 10.5009/gnl.2011.5.1.15] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
106 Kusakabe A, Nojiri S, Iio E, Matsuura K, Shinkai N, Miyaki T, Joh T. Case-control study of the RFA therapeutic effect of newly developed 4D US and conventional 2D US. J Med Ultrason (2001) 2013;40:39-46. [PMID: 27276923 DOI: 10.1007/s10396-012-0388-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
107 Takechi M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, Mochizuki T. Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Jpn J Radiol. 2012;30:743-751. [PMID: 23001373 DOI: 10.1007/s11604-012-0120-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
108 Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116:3006-3014. [PMID: 20564406 DOI: 10.1002/cncr.25044] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
109 Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Yoshida H, Aoki T, Hasegawa K, Akahane M, Ohtomo K, Fukayama M, Koike K, Kokudo N. Diagnostic accuracy of α-fetoprotein and des-γ-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates: AFP and DCP in transplant candidates. Hepatology Research 2011;41:1199-207. [DOI: 10.1111/j.1872-034x.2011.00871.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
110 Chiorean L, Caraiani C, Radziņa M, Jedrzejczyk M, Schreiber-dietrich D, Dietrich CF. Vascular phases in imaging and their role in focal liver lesions assessment. CH 2016;62:299-326. [DOI: 10.3233/ch-151971] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
111 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
112 Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108:416-424. [PMID: 23318478 DOI: 10.1038/ajg.2012.445] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
113 Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, Watanabe M, Shibuya A, Minamino T, Saigenji K. Repeat Radiofrequency Ablation Provides Survival Benefit in Patients With Intrahepatic Distant Recurrence of Hepatocellular Carcinoma. Am J Gastroenterol 2009;104:2747-53. [DOI: 10.1038/ajg.2009.414] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
114 Min JH, Lee MW, Cha DI, Jeon YH, Shin SW, Cho SK, Rhim H, Lim HK. Radiofrequency ablation combined with chemoembolization for intermediate-sized (3-5 cm) hepatocellular carcinomas under dual guidance of biplane fluoroscopy and ultrasonography. Korean J Radiol. 2013;14:248-258. [PMID: 23483753 DOI: 10.3348/kjr.2013.14.2.248] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
115 Kim PN, Choi D, Rhim H, Rha SE, Hong HP, Lee J, Choi JI, Kim JW, Seo JW, Lee EJ, Lim HK. Planning ultrasound for percutaneous radiofrequency ablation to treat small (≤ 3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess factors affecting ultrasound visibility. J Vasc Interv Radiol 2012;23:627-34. [PMID: 22387030 DOI: 10.1016/j.jvir.2011.12.026] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
116 Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H; Peretinoin Study Group. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: A randomized double-blind placebo-controlled study. J Gastroenterol. 2015;50:191-202. [PMID: 24728665 DOI: 10.1007/s00535-014-0956-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
117 Kudo M. Future treatment option for hepatocellular carcinoma: a focus on brivanib. Dig Dis. 2011;29:316-320. [PMID: 21829023 DOI: 10.1159/000327568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
118 Hatanaka K, Kudo M, Minami Y, Ueda T, Tatsumi C, Kitai S, Takahashi S, Inoue T, Hagiwara S, Chung H. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology. 2008;51 Suppl 1:61-69. [PMID: 18544950 DOI: 10.1159/000122600] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 7.0] [Reference Citation Analysis]
119 Cacciola A, Parisi S, Tamburella C, Lillo S, Ferini G, Molino L, Iatì G, Pontoriero A, Bottari A, Mazziotti S, Cicero G, Minutoli F, Blandino A, Pergolizzi S. Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when? Rep Pract Oncol Radiother 2020;25:299-306. [PMID: 32194349 DOI: 10.1016/j.rpor.2020.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339-364. [PMID: 21829027 DOI: 10.1159/000327577] [Cited by in Crossref: 477] [Cited by in F6Publishing: 491] [Article Influence: 43.4] [Reference Citation Analysis]
121 Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2011;81 Suppl 1:158-164. [PMID: 22212951 DOI: 10.1159/000333280] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
122 Saito M, Seo Y, Yano Y, Miki A, Yoshida M, Azuma T. A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment. J Gastroenterol 2012;47:1134-42. [DOI: 10.1007/s00535-012-0577-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
123 Wang C, Lu Y, Chen Y, Feng Y, An L, Wang X, Su S, Bai W, Zhou L, Yang Y. Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin Exp Metastasis. 2009;26:839-848. [PMID: 19784786 DOI: 10.1007/s10585-009-9283-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
124 Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol. 2009;44 Suppl 19:112-118. [PMID: 19148804 DOI: 10.1007/s00535-008-2274-6] [Cited by in Crossref: 148] [Cited by in F6Publishing: 144] [Article Influence: 11.4] [Reference Citation Analysis]
125 Chung YE, Kim MJ, Park MS, Choi JY, Lim JS, Kim KA, Kim KW. The impact of CT follow-up interval on stages of hepatocellular carcinomas detected during the surveillance of patients with liver cirrhosis. AJR Am J Roentgenol 2012;199:816-21. [PMID: 22997373 DOI: 10.2214/AJR.11.8100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Rhim H, Lim HK, Choi D. Current status of radiofrequency ablation of hepatocellular carcinoma. World J Gastrointest Surg 2010; 2(4): 128-136 [PMID: 21160861 DOI: 10.4240/wjgs.v2.i4.128] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
127 Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: a literature review. Int J Hepatol. 2011;2011:104685. [PMID: 21994847 DOI: 10.4061/2011/104685] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]